<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801528</url>
  </required_header>
  <id_info>
    <org_study_id>MMC-0202-07</org_study_id>
    <nct_id>NCT00801528</nct_id>
  </id_info>
  <brief_title>Diclofenac vs. Ropivacaine for Cesarean Section</brief_title>
  <official_title>The Analgesic Efficacy of Continuous Wound Instillation With Diclofenac or Ropivacaine Following Cesarean Section: a Randomized, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, double blind study designed to investigate analgesic efficacy of
      wound infusion using diclofenac or ropivacaine following Cesarean section performed via a
      Pfannenstiel incision.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objective: To assess the analgesic efficacy of diclofenac or ropivacaine when
      administered via wound infusion.

      Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Large
      referral hospital. Patients: 75 women recovering from Cesarean section performed via a
      Pfannenstiel incision.

      Interventions: On completion of the surgical procedure, a 15 cm 19G infusion catheter
      (PAINfusorâ„¢, Baxter) will be placed below the fascia. According to a computer generated
      randomization schedule, patients will be divided into one of three treatment groups (n = 25).

        -  In Group Control water for injection will be administered.

        -  In Group Ropivacaine 0.2 % ropivacaine will be administered.

        -  In Group Diclofenac diclofenac (300 mg/240 ml of water for injection) will be
           administered.

      During the first 6 postoperative hours, a co-investigator will administer &quot;rescue&quot; analgesia
      (10 ml bolus of infusion drug or rescue morphine). Thereafter, the catheter will be connected
      to an elastometric pump (LV 10 Infusor, Baxter) filled with either water for injection,
      ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection). The fluid will be
      administered as a constant infusion rate (10 mL/hr). Continuous wound infusion will be
      continued for the subsequent 18 postoperative hours. During this 18 hour period, subcutaneous
      morphine 4 mg will be administered on patient request for additional analgesia.

      Measurements and Main Results: The following parameters will be assessed and recorded:

        1. Demographic data

        2. Surgical milestones(Anesthetic time, surgical time etc).

        3. Incidence of failed intrathecal anesthesia

        4. VAS for pain every 15 min during first 6 postoperative hours

        5. Time to first pain (intrathecal anesthesia to VAS &gt; 60 mm)

        6. Number of infusion events (10 mL and 5 mL)

        7. Rescue morphine administration during first 6 postoperative hours.

        8. Subcutaneous morphine administration during subsequent 18 postoperative hours.

        9. VAS for pain.

       10. The incidence of nausea and vomiting.

       11. Patient satisfaction at 24 hours, postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1)Pain intensity 2)&quot;Rescue&quot; analgesia requirements</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous wound instillation of ropivacaine 0.2 % at a rate set of 10 mL/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous wound instillation of diclofenac (300 mg/240 ml water for injection) at a rate set of 10 mL/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water for injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continuous wound instillation of water for injection at a rate set of 10 mL/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine, Diclofenac, Water for injection</intervention_name>
    <description>Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_label>Diclofenac</arm_group_label>
    <arm_group_label>Water for injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing Cesarean section

        Exclusion Criteria:

        A history of clinically significant disease:

          -  cardiovascular

          -  pulmonary

          -  hepatic

          -  renal

          -  neurologic

          -  psychiatric

          -  metabolic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>May 2, 2010</last_update_submitted>
  <last_update_submitted_qc>May 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alex Khaikin MD</name_title>
    <organization>Meir Medical Center</organization>
  </responsible_party>
  <keyword>ropivacaine</keyword>
  <keyword>diclofenac</keyword>
  <keyword>local anesthetic instillation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

